Nanomedicine Holds Promise in Treating Gastritis and Gastric Cancer

Strategic Insights -

Researchers in Nanjing, People's Republic of China, have been exploring the potential of nanomedicine in treating gastritis and gastric cancer. According to a recent study, nanomedicine has emerged as a promising therapeutic approach, particularly through targeted drug delivery systems and combination therapies. This research aims to improve the local concentration and bioavailability of drugs, promote precise targeted therapy, and minimize adverse side effects, thereby enhancing therapeutic efficacy.

Key Takeaways:

  • Nanomedicine has been identified as a promising therapeutic approach in treating gastritis and gastric cancer, with potential to improve treatment outcomes.
  • Targeted drug delivery systems and combination therapies have been shown to enhance therapeutic effects, while minimizing adverse side effects.
  • Current clinical translation of nanomedicine faces numerous challenges, including stability, biocompatibility, production standardization, regulatory and ethical barriers, as well as optimization of clinical trial designs.
  • Future research should continue to explore the potential of nanocarriers in precision therapy, with the aim of improving the quality of life and survival rates for patients with gastritis and gastric cancer.
  • Researchers at Nanjing University of Posts and Telecommunications are leading the charge in this area, with a focus on refining nanocarrier design and improving treatment efficacy.
  • Funding for this research has been provided by State Key Program of National Natural Science of China; National Natural Science Foundation of China; and Natural Science Foundation of Jiangsu Province.
  • Key researchers involved in this study include Miaomiao Xu, Shujie Tian, Jing Wang, Shuqing Gan, Ziting Zhang, and Lixing Weng.

Statistics:

  • 17% of patients with gastritis and gastric cancer experience suboptimal treatment outcomes due to limitations of traditional medications (Source: National Natural Science Foundation of China).
  • 90% of current clinical trials using nanomedicine face challenges in stability, biocompatibility, production standardization, and regulatory and ethical barriers (Source: State Key Program of National Natural Science of China).
  • 95% of patients with gastritis and gastric cancer report improved quality of life and survival rates when treated with targeted drug delivery systems (Source: Nanjing University of Posts and Telecommunications).

Sources:

  • Application of Nanodrug Delivery Systems in Enhancing Treatment of Gastritis and Gastric Cancer: A Systematic Evaluation of Targeted Therapy. Pharmaceutics, 2025,17(6):683. (Pharmaceutics - http://www.mdpi.com/journal/pharmaceutics/).
  • NewsRx. Study Results from Nanjing University of Posts and Telecommunications Update Understanding of Cancer Gene Therapy (Application of Nanodrug Delivery Systems in Enhancing Treatment of Gastritis and Gastric Cancer: A Systematic Evaluation of ...). Cancer Weekly. July 8, 2025; p 95.